期刊文献+

分子生物学技术在病毒性传染病中的临床应用 被引量:5

Clinical Applications of Molecular Biology for Viral Infectious Diseases
在线阅读 下载PDF
导出
摘要 分子生物学方法目前是病毒检测和定性的一部分。PCR 技术可以检测传统病毒学方法检测不到的病毒,为病毒学进一步研究提供了技术平台。分子方法不仅能检测到抗生素抗性基因,而且还能进行病毒株基因分型,为公众提供健康信息。通过对抗病毒治疗应答的监控可检测到病毒抑制和病毒量,大大提高病毒的治疗水平。随着多重 PCR、实时定量荧光 PCR 出现和自动化效率的提高,分子检测方法价格将不断降低,分子方法发挥的作用将进步增加。这篇文章将重点叙述分子生物学方法在临床病毒学检测中的应用情况,通过一些例子阐明这些方法如何改变实验室诊断,达到防治病毒性传染病的目的。 Molecular biological methods are now part of virus detection and characterisation. Polymerase chain reaction (PCR) techniques have led the way into this new era by allowing rapid detection of virus that were previously difficult or impossible to detect by traditional virological methods, Molecular methods have now progressed beyond identification to detect antibiotic resistance genes and provide public health information such as strain characterisation by genotyping. Treatment of certain virus has been improved by viral resistance detection and viral load testing for the monitoring of responses to antiviral therapies, With the advent of multiplex PCR, real-time PCR and improvements in efficiency through automation, the costs of molecular methods are decreasing such that the role of molecular methods will further increase, This review will focus on the clinical utility of molecular methods performed in the clinical virology laboratory, illustrated with the many examples of how they have changed laboratory diagnosis and therefore the management of viral infectious diseases.
出处 《吉林畜牧兽医》 2006年第11期16-18,共3页 Jilin Animal Husbandry and Veterinary Medicine
关键词 分子生物学 病毒 临床应用 molecular biology virus clinical applications
  • 相关文献

参考文献12

  • 1Gilbert GL, James GS, Sintchenko V. Culture shock. Molecular methods for diagnosis of infectious diseases. Med J Aust. 1999;171:536-540.
  • 2Dax EM. The window period and HIV tests. ASHM Journal Club. 2004; 13:9-11.
  • 3Seed CR, Cheng A, Ismay SL, et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion.2002;42:1365-1372.
  • 4Ng EK, Hui DS, Chart KC, et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem. 2003;49:1976-1980.
  • 5Ho PL, Chau PH, Yip PSF, et al. A prediction rule for clinical diagnosis of severe acute respiratory syndrome. Eur Respit J. 2005;26:474-479.
  • 6Katzenstein TL. Molecular biological assessment methods and understanding the course of the HIV infection. APMIS.2003; 114(S): 1-37.
  • 7Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med. 2002;347:975-982.
  • 8Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med. 2002;347:975-982.
  • 9Dixon JS,Boehme RE.Lamivudine for the treatment of chronic hepatitis B. Acta Gastroenterol Belg. 2000;63:348-358.
  • 10Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management ofpre-core mutant chronic hepatitis B. J Viral Hepat. 2001;8:311-321.

同被引文献18

引证文献5

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部